Newscast – Page 108 – media

UK’s NHS Aims to Build a Library of Reliable Mobile Health Apps.

The UK's National Health Service is putting out the call for more mobile health apps for its NHS Apps Library, and has chosen an agency to certify those apps. The library now features 46 mHealth apps - only one of which has passed muster.
- Source: mHealth Intelligence
- 658
- February 27, 2018
Company Insight digital health mHealth
Cedars-Sinai, Emulate partner to give precision medicine a boost with organs-on-chips tech

The technology could enable researchers to test drugs or treatments on a patient’s cells to avoid harmful, ineffective and costly options while determining personalized regimens.
- Source: Healthcare IT News
- 556
- February 27, 2018
digital health medtech precision medicine Researches
Gilead links with Sangamo in gene therapy alliance

Gilead’s Kite is linking with Sangamo Therapeutics in a collaboration that aims to develop next-generation engineered cell therapies for the treatment of cancer.
- Source: drugdu
- 554
- February 26, 2018
cancer engineered cell therapies Gilead Market Views
AI Biotech XtalPi Closes Series B Round Funding from Sequoia China, Google, and Tencent

XtalPi Inc., a computation-driven pharmaceutical technology company, announced that it has closed a Series B funding round of 15 million USD led by Sequoia China, with participation from Google and existing investor Tencent. To date, XtalPi has raised over 20 million USD, making it one of the top-funded AI-powered biotechs.
- Source: finance.yahoo
- 533
- February 26, 2018
biotechs Market Views Series
Merck Drops $394 Million to Acquire Virus-Based Cancer Company Viralytics

Merck & Company is driving forward in its quest to develop a premier immuno-oncology pipeline. The company plunked down $394 million to acquire Australia-based Viralytics Ltd and its oncolytic immunotherapy treatments.
- Source: Biospace;
- 735
- February 26, 2018
immuno-oncology pipelin immunotherapy Market Views Merk
U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection

Gilead Sciences, Inc.(NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection. Biktarvy combines the novel, unboosted integrase strand transfer inhibitor (INSTI) bictegravir, with the demonstrated safety and efficacy profile of the Descovy® (FTC/TAF) dual nucleoside reverse transcriptase inhibitor (NRTI) backbone, and is the smallest INSTI-based triple-therapy STR available.
- Source: gilead
- 912
- February 26, 2018
Biktarvy FDA Gilead Sciences HIV-1 infection
What’s Driving the Global Surgical Robotics Market

According to a new market research report by BIS Research, the global surgical robotics market is expected to reach a value of $12.6 billion by the year 2025.
- Source: marketresearch.com
- 1,255
- February 26, 2018
healthcare technologies and innovations Market Reports Market Views surgical
Using “Nanodrops” to Repair Corneas Could Ultimately Replace Glasses

Quite a number of people develop nearsightedness or farsightedness during their lifetimes. "Nanodrops," a new eye drop developed by Israeli ophthalmologists, has successfully fixed corneas in pig eyes, and could potentially do the same for people.
- Source: Futurism
- 531
- February 26, 2018
eye contact healthcare technologies and innovations medtech Researches
Gut bacteria helps fight off sepsis in mice

Sepsis, a potentially life-threatening complication of infection, is currently treated with antibiotics which kill the infection-causing bacteria. But research out of the University of Pennsylvania spotlights an alternative approach: Delivering certain gut microbes to mice boosted antibody levels in mice, protecting them against the widespread inflammation that can lead to sepsis.
- Source: fiercebiotech
- 548
- February 24, 2018
antibiotics Researches sepsis
Priority review for Shire’s HAE drug

US regulators are undertaking a speedy review of Shire’s lanadelumab (SHP643) for the prevention of angioedema attacks in patients 12 years and older with hereditary angioedema (HAE).
- Source: pharmatimes
- 792
- February 24, 2018
angioedema HAE Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.